Resalis Therapeutics
Torino · Founded 2021
About Resalis Therapeutics
Resalis Therapeutics changes the way metabolic diseases are treated by targeting a key regulator of pathways that contribute to obesity and fatty liver disease. RES-010, the company's flagship program, is being developed using its expertise in non-coding RNA drug modality and lipid metabolism to provide a safe and convenient treatment option with disease-modifying therapeutic effects, such as long-term weight loss and reduced hepatic steatosis. Resalis is rapidly moving RES-010 into clinical trials for a variety of metabolic disorders, backed by strong preclinical evidence.
Company Facts
- Founded: 2021
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $28.7M
- Last round: Corporate Round (Oct 2024)
- Website: https://www.resalistherapeutics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/resalis-therapeutics-17560 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.